[en] Disorders of the phosphocalcic metabolism are frequent in dialysis patients. Such disorders are difficult to treat and have negative impact on bone health, but also on cardiovascular mortality. Hyperphosphoremia is a strong predictor of cardiovascular mortality. New phosphate binders are now available in Belgium. A new molecule acting on the calcium receptor of the parathyroid glands is able to control secondary and tertiary hyperparathyroidism in dialysis patients. These new therapies, specific for dialysis patients, will be reviewed in this article.
Disciplines :
Urology & nephrology
Author, co-author :
Delanaye, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Néphrologie
Van Overmeire, Lionel ; Centre Hospitalier Universitaire de Liège - CHU > Frais communs médecine
Dubois, Bernard ; Centre Hospitalier Universitaire de Liège - CHU > Néphrologie
Krzesinski, Jean-Marie ; Université de Liège - ULiège > Département des sciences cliniques > Néphrologie
Language :
French
Title :
Nouveautés dans la prise en charge des anomalies du bilan phosphocalcique chez le patient dialysé
Alternative titles :
[en] New Management of Phosphocalcic Abnormalities in Dialysis Patient
Publication date :
2007
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis, 2003, 42, S1-201.
Goodman WG. - Medical management of secondary hyperparathyroidism in chronic renal failure. Nephrol Dial Transplant, 2003, 18, 2-8.
Oprisiu R, Hottelart C, Ghitsu S, et al. - Ostéodystrophie rénale (I): diagnostic invasif et non invasif des variétés histopathologiques. Néphrologie, 2000, 21, 229-237.
Block GA, Hulbert-Shearon TE, Levin NW, et al. - Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis, 1998, 31, 607-617.
Block GA, Klassen PS, Lazarus JM, et al. - Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol, 2004, 15, 2208-2218.
Ganesh SK, Stack AG, Levin NW, et al. - Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol, 2001, 12, 2131-2138.
Cozzolino M, Brancaccio D, Gallieni M, et al. - Pathogenesis of vascular calcification in chronic kidney disease. Kidney Int, 2005, 68, 429-436.
Young EW, Albert JM, Satayathum S, et al. - Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int, 2005, 67, 1179-1187.
Delanaye P, Krzesinski JM. - Nouveautés à propos du métabolisme du phosphore. Rev Med Liege, 2005, 60, 189-197.
D'Haese PC, Couttenye MM, De Broe ME. - Diagnosis and treatment of aluminium bone disease. Nephrol Dial Transplant, 1996, 11, 74-79.
Katopodis KP, Andrikos E, Pappas M, et al. - Effectiveness of aluminum hydroxide timing administration in relation to meals in controlling hyperphosphatemia in dialysis patients. Int J Artif Organs, 2005, 28, 803-807.
Goodman WG, Goldin J, Kuizon BD, et al. - Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med, 2000, 342, 1478-1483.
Ribeiro S, Ramos A, Brandao A, et al. - Cardiac valve calcification in haemodialysis patients; role of calcium-phosphate metabolism. Nephrol Dial Transplant, 1998, 13, 2037-2040.
Nolan CR, Qunibi WY. - Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis. Kidney Int Suppl, 2005, S13-S20.
Chertow GM, Burke SK, Dillon MA, et al. - Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant, 1999, 14, 2907-2914.
Sadek T, Mazouz H, Bahloul H, et al. - Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study. Nephrol Dial Transplant, 2003, 18, 582-588.
Hergesell O, Ritz E. - Phosphate binders in uraemia: pharmacodynamics, pharmacoeconomics, pharmacoethics. Nephrol Dial Transplant, 2002, 17, 14-17.
Block GA, Raggi P, Bellasi A, et al. - Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int, 2007, 71, 438-441.
Qunibi WY, Hootkins RE, McDowell LL, et al. - Treatment of hyperphosphatemia in hemodialysis patients: The Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int, 2004, 65, 1914-1926.
Persy VP, Behets GJ, Bervoets AR, et al. - Lanthanum: a safe phosphate binder. Semin Dial, 2006, 19, 195-199.
Al Baaj F, Speake M, Hutchison AJ. - Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study. Nephrol Dial Transplant, 2005, 20, 775-782.
Hutchison AJ, Maes B, Vanwalleghem J, et al. - Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract, 2005, 100, c8-19.
Lacour B, Lucas A, Auchere D, et al. - Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int, 2005, 67, 1062-1069.
Brancaccio D, Cozzolino M. - Lanthanum carbonate: time to abandon prejudices? Kidney Int, 2007, 71, 190-192.
Finn WF. - Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol, 2006, 65, 191-202.
Spasovski GB, Sikole A, Gelev S, et al. - Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant, 2006, 21, 2217-2224.
Malluche HH, Mawad H, Koszewski NJ. - Update on vitamin D and its newer analogues: actions and rationale for treatment in chronic renal failure. Kidney Int, 2002, 62, 367-374.
Steddon SJ, Cunningham J. - Calcimimetics and calcilytics - fooling the calcium receptor. Lancet, 2005, 365, 2237-2239.
Moe SM, Chertow GM, Coburn JW, et al. - Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int, 2005, 67, 760-771.
Block GA, Martin KJ, de Francisco AL, et al. - Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med, 2004, 350, 1516-1525.
Lindberg JS, Culleton B, Wong G, et al. - Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol, 2005, 16, 800-807.
Strippoli GF, Palmer S, Tong A, et al. - Meta-analysis of biochemical and patient-level effects of calcimimetic therapy. Am J Kidney Dis, 2006, 47, 715-726.
White CA, Jaffey J, Magner P. - Cost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis patients. Kidney Int, 2007, 71, 312-317.
